Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Update

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) was the target of a large drop in short interest during the month of February. As of February 27th, there was short interest totaling 99,192 shares, a drop of 21.0% from the February 12th total of 125,617 shares. Currently, 0.2% of the shares of the company are short sold. Based on an average trading volume of 13,625 shares, the days-to-cover ratio is presently 7.3 days. Based on an average trading volume of 13,625 shares, the days-to-cover ratio is presently 7.3 days. Currently, 0.2% of the shares of the company are short sold.

Institutional Investors Weigh In On Innate Pharma

Institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC purchased a new stake in Innate Pharma in the fourth quarter valued at $36,000. OLD Mission Capital LLC acquired a new stake in Innate Pharma in the fourth quarter valued at approximately $50,000. Finally, Jane Street Group LLC acquired a new stake in Innate Pharma in the 4th quarter valued at $162,000. Institutional investors and hedge funds own 0.16% of the company’s stock.

Innate Pharma Stock Performance

Shares of NASDAQ:IPHA remained flat at $1.50 on Friday. The stock had a trading volume of 38,792 shares, compared to its average volume of 15,063. The business has a 50-day moving average of $1.71 and a 200 day moving average of $1.86. Innate Pharma has a twelve month low of $1.40 and a twelve month high of $2.63.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Innate Pharma in a research note on Thursday, January 22nd. BTIG Research began coverage on shares of Innate Pharma in a report on Thursday. They issued a “buy” rating and a $8.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Innate Pharma Company Profile

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.